✦ LIBER ✦

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

✍ Scribed by Karla Eggert; David Squillacote; Paolo Barone; Richard Dodel; Regina Katzenschlager; Murat Emre; Andrew J. Lees; Olivier Rascol; Werner Poewe; Eduardo Tolosa; Claudia Trenkwalder; Marco Onofrj; Fabrizio Stocchi; Giuseppe Nappi; Vladimir Kostic; Jagoda Potic; Evzen Ruzicka; Wolfgang Oertel;; in cooperation with the German Competence Network on Parkinson's Disease

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 117 KB
Volume: 25
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.22974

No coin nor oath required. For personal study only.

✦ Synopsis

Squillacote, received compensation from Eisai for their site's conduct of the study. Drs. Barone, Lees, and Oertel received honoraria from Eisai as members of the Advisory Board of this study. Dr. Rascol has received unrestricted scientific grant and honoraria from Eisai for his advice to the company on this project. Dr. Dodel received honoraria from Eisai for presenting the study at meetings. Drs. Katzenschlager, Poewe, Kostic, and Ruzicka received honoraria from Eisai for consulting in relation to this study. Dr. Emre has been on the Protocol Development and Advisory Committee for the study and received honoraria for his advice. Dr. Onofrj received honoraria from Eisai in his capacity as Principal Investigator.

📜 SIMILAR VOLUMES

Clinical efficacy of istradefylline (KW-

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

✍ Yoshikuni Mizuno; Kazuko Hasegawa; Tomoyoshi Kondo; Sadako Kuno; Mitsutoshi Yama 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

## Abstract The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to

Randomized, double-blind study of pramip

Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

✍ Yoshikuni Mizuno; Nobuo Yanagisawa; Sadako Kuno; Mitsutoshi Yamamoto; Kazuko Has 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment. ©

Macrogol for the treatment of constipati

Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study

✍ Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Ri 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Abstract Chronic constipation is the most frequent symptom of autonomic system involvement in Parkinson's disease (PD). Quite often the symptom is severe and impairs patients' quality of life. The objective of this study is to determine the efficacy and safety of an isosmotic macrogol solution f

Blind randomized controlled study of the

Blind randomized controlled study of the efficacy of cognitive training in Parkinson's disease

✍ Anna Prats París; Heidi Guerra Saleta; Maria de la Cruz Crespo Maraver; Emmanuel 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 1 views

## Abstract The aim of this study was to analyze the efficacy of a cognitive training program on cognitive performance and quality of life in nondemented Parkinson's disease patients. Participants who met UK Brain Bank diagnosis criteria for Parkinson's disease, with I–III Hoehn & Yahr, aged 50–80,

Botulinum toxin type A for drooling in P

Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study

✍ Giovanni Lagalla; Marzia Millevolte; Marianna Capecci; Leandro Provinciali; Mari 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double-blind, randomized, placebo-controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gla

Rotigotine transdermal patch in early Pa

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole

✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,